104 completed, 21 unknown, 14 active not recruiting, 11 terminated. 58 Phase 2, 32 Phase 3, 25 Phase 4, 15 Not applicable, 15 Phase 1.
Follow Janssen, LP: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Computerized Decision Support to Prevent Stroke in Atrial Fibrillation Alert-based computerized decision support - Atrial Fibrillation, Stroke | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 2500 | 2026-12-30 | 2026-02-25 |
| Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Abiraterone Acetate - Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation | Phase 2 | Withdrawn | Qian Qin | 2025-10-01 | 2026-04-08 | |
| Daratumumab for Polyneuropathy Associated With MGUS Daratumumab and hyaluronidase-fihj - Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Withdrawn | Georgetown University | 2025-09-26 | 2025-10-01 | |
| Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer Niraparib/Abirate rone acetate fixed-dose combination, Prednisone - Prostate Cancer, Castrate Resistant Prostate Cancer | Phase 2 | Withdrawn | Latin American Cooperative Oncology Group | 2025-04-30 | 2025-09-29 | |
| Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy Plasma exchange, Daratumumab - Multiple Myeloma, Light Chain Nephropathy | Completed | Brigham and Women's Hospital | 549 | 2024-06-01 | 2026-07-09 | |
| Real-life Management of Patients Eligible for CAR-T Cell Therapy Patients eligible for CAR-T treatment - Hemopathy | Recruiting | University Hospital, Toulouse | 550 | 2024-04-30 | 2025-04-10 | |
| Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer Daratumumab, KRAS vaccine, Nivolumab - Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Georgetown University | 19 | 2024-01-31 | 2026-06-30 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent - Extramedullary Myeloma | Phase 1 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 10 | 2023-12-08 | 2026-07-28 |
| Assessment of Visual Performance With Virtual Reality After Cataract Surgery cataract surgery with implantation of intraocular lens - Cataract | Not applicable | Unknown | The University of Hong Kong | 114 | 2023-10-01 | 2023-08-29 |
| Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Active not recruiting | Royal Marsden NHS Foundation Trust | 170 | 2023-09-26 | 2025-09-18 | |
| Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease COVID-19 Vaccine - Inflammatory Bowel Diseases | Unknown | GI Alliance | 400 | 2023-07-05 | 2023-06-18 | |
| Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL Daratumumab / Hyaluronidase Injection - T-cell Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Eastern Cooperative Oncology Group | 20 | 2023-05-25 | 2026-09-15 |
| Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations Amivantamab, Lazertinib, Pemetrexed 500 mg - Metastatic Non-small Cell Lung Cancers | Phase 2 | Completed | Latin American Cooperative Oncology Group | 54 | 2023-05-24 | 2026-08-28 |
| Value Based Healthcare in Psoriasis Patients receiving PsoPlus care - Psoriasis | Not applicable | Unknown | University Hospital, Ghent | 350 | 2023-03-01 | 2024-05-10 |
| European Myeloma Network (EMN) Sample Project storage of biological samples - Multiple Myeloma, Smoldering Multiple Myeloma | Recruiting | European Myeloma Network B.V. | 6000 | 2022-12-21 | 2025-12-03 | |
| Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM Daratumumab, Pomalidomide - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Alliance Foundation Trials, LLC. | 2022-10-01 | 2023-01-27 | |
| Endothelin-1 and Cardiac Allograft Vasculopathy (CAV) Macitentan - Cardiac Allograft Vasculopathy | Phase 4 | Completed | University of California, Los Angeles | 19 | 2022-05-19 | 2024-03-12 |
| A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma Daratumumab, Pomalidomide, All-trans retinoic acid - Multiple Myeloma | Phase 2 | Terminated | Hackensack Meridian Health | 1 | 2022-05-02 | 2025-02-25 |
| AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry Chronic Lymphocytic Leukemia | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 472 | 2022-03-24 | 2026-10-16 |
Showing 20 of 166. Sign in to see all of them.
Schizophrenia (27) · Multiple Myeloma (21) · Psychotic Disorders (19) · HIV Infections (12) · Acquired Immunodeficiency Syndrome (9) · Neoplasms (8) · Depression (7) · Prostatic Neoplasms (7) · Bipolar Disorder (5) · Carcinoma, Non-Small-Cell Lung (5) · Lymphoma, Mantle-Cell (5) · Recurrence (5) · Depressive Disorder, Major (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Stress Disorders, Post-Traumatic (4)
Risperidone (38) · daratumumab (21) · Dexamethasone (16) · ibrutinib (12) · Bortezomib (11) · Lenalidomide (8) · Itraconazole (6) · Prednisone (5) · niraparib (5) · pomalidomide (5) · Abiraterone Acetate (4) · Calcium Dobesilate (4) · Cisplatin (4) · Cyclophosphamide (4) · Melphalan (4)
United States (75) · France (20) · United Kingdom (15) · Canada (10) · Spain (10) · Italy (9) · Belgium (8) · Germany (7) · South Korea (7) · Austria (6) · Netherlands (6) · Australia (5) · Brazil (5) · Greece (5) · Hong Kong (5)
Richard Greil, MD (2) · William H Wilson, PhD (2) · Ajay Nooka, MD, MPH (1) · Alan I. Green, MD (1) · Alan Winston, MD (1)
PMID 26934062, PMID 33357481, PMID 10084637, PMID 12729424, PMID 12777271, PMID 15367925, PMID 1542320, PMID 16965196, PMID 17054789, PMID 17375138, PMID 17854242, PMID 17898351, PMID 17917554, PMID 17975181, PMID 18007568, PMID 18278987, PMID 18294021, PMID 18590519, PMID 18642974, PMID 19411369, PMID 19906343, PMID 19922552, PMID 20492853, PMID 21377137, PMID 21463526, PMID 21813427, PMID 21999346, PMID 21999370, PMID 22508869, PMID 22688151, PMID 22938760, PMID 23134268, PMID 23551034, PMID 23848131, PMID 23849714, PMID 23889978, PMID 24684267, PMID 25185962, PMID 25482239, PMID 25776200, PMID 25886087, PMID 26141003, PMID 26238974, PMID 26302441, PMID 26367799, PMID 26497198, PMID 26890894, PMID 27120993, PMID 27258623, PMID 27269947
2014 (2), 2017 (2), 2005 (1), 2015 (1), 2018 (1), 2019 (1), M01RR000036 (1), P30CA093373 (1), P30CA138292 (1), R01AG046179 (1), R01AG053267 (1), R21MH080026 (1), R35CA197353 (1), R56AG053267 (1), U01AG042791 (1)